Jeito
  • About
  • The team
  • Our portfolio
  • ESG & Impact
  • Newsroom
  • Contact
  • English
    • Français
    • English
Select Page

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

by Jeito Life | 29 Nov Tue | English

Deal validates Jeito’s unique investment model of selecting high-quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito Capital (“Jeito”), the largest fully independent...

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

by Jeito Life | 11 Oct Tue | English

Aarhus, Denmark, 11 October 2022 – NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today reported positive top-line results from a Phase I/IIa clinical trial of NMD670,...

Jeito Capital co-leads €75 million Series B financing in SparingVision

by Jeito Life | 14 Sep Wed | English

Paris, France, September 14, 2022 – Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech...

Jeito Capital co-leads $76 million Series A financing for CDR-Life its 10th investment since its launch

by Jeito Life | 13 Apr Wed | English

Paris, France, April 13, 2022 – Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a $76 million Series A financing round in CDR-Life, a privately-held biotech...

Jeito Capital co-leads EUR 80 million euro Series B financing in European oncology company, Precirix

by Jeito Life | 16 Mar Wed | English

Paris, France, March 2022, 16th – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led an investment of €80 million in Precirix, a clinical-stage biotechnology company developing...
« Older Entries

Recent Posts

  • Jeito Capital promotes Ksenija Pavletic to General Partner
  • Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
  • Jeito Capital appoints Pascal Touchon as Operating Partner
  • Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
  • Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders

Recent Comments

    Mentions et autres liens
    We use cookies to provide you with the best possible website experience by
    offering you tailored content and for statistical purposes. You can modify your
    choices at any time. For more information, please consult our cookie policy.
    Cookie settingsAccept allReject all
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while browsing the site. Among these, cookies that are categorized as necessary are stored on your browser as they are essential for the basic functionality of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option to decline these cookies. However, disabling some of these cookies may affect your browsing experience.
    Necessary
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    SAVE & ACCEPT